Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (562)	12/20/1999 8:33:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 626

<<Based upon the excellent accrual and lack of safety concerns to date, the study is being expanded to a Phase III study. Details of the expanded study protocol are currently being finalized with the FDA.>> Well,so far so good. At the end maybe something will materialize here! Also, have in mind that we are now 6-9 months away from sec and third PIII Ilo trials results. 00 will be an interesting year for TTP. Very interesting. Miljenko

To: Arthur Radley who wrote (562)	12/23/1999 3:16:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 626

TD: I hope that this transition of phase II to phase III will not delay an evaluation of efficacy by even one day. It's an old trick for bait and switch companies to make it appear that more balls are in the air than is actually the case. Ilo is a nice ball. Like MZ, I'm interested in hearing more about piv. The company needs to evaluate the results of this 200 plus patient trial at the earliest opportunity. Is this decision the most expeditious route to evaluate the science, or is it based on what would look best in a prospectus? Kudos to the company for getting enrollment to this point! Rick